Malta, 26 June 2007

Circular No. P07/2007

Dear Healthcare Professional,

Re: Suspension of the Marketing Authorisation for Viracept® (nelfinavir)

Following the recent recall of Viracept® following contamination of certain batches with ethyl mesilate, a known genotoxic substance, the European Medicines Agency (EMEA) has agreed to suspend this product. An action plan to follow up patients exposed to contaminated Viracept® as well as studies to determine the toxic dose of ethyl mesilate have been agreed upon. The Medicines Authority has participated in these discussions held at the EMEA and is in agreement with the actions described in the attached **press release** and **Q & A document** on Viracept® issued by the EMEA. The Medicines Authority will notify healthcare providers and patients in a timely fashion as new information becomes available.

Medicines Authority
198, Rue D'Argens, Gzira, GZR 03 – Malta.
Tel. (+356) 23439000 Fax. (+356) 23439161 email: info.mru@gov.mt